Published 2025-02-01
“…Xiayu Xu,1 Longyang Zhu,2 Sizhao
Li,3 Guochun Wang,3 Yongpeng Ge3 1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province,
People’s Republic of China; 2Peking University, China-Japan Friendship School of Clinical Medicine, Beijing,
People’s Republic of China; 3Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing,
People’s Republic of ChinaCorrespondence: Yongpeng Ge, Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029,
People’s Republic of China, Email gyp2016@163.comObjective: To investigate the clinical features and prognosis of anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-cyclic citrullinated peptide (CCP) antibody double-positive dermatomyositis (DM) (MDA5+/CCP+ DM).Methods: A retrospective analysis of 264 consecutive cases of MDA5+ DM hospitalized from March 2018 to March 2022, and patients with anti-CCP antibodies were screened out. …”
Get full text
Article